Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rifkin

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Annals of Hematology|July 30, 2018
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM RegistryRafat Abonour, Lynne Wagner, Brian G M Durie, et al.
Clinical Therapeutics|July 16, 2018
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM RegistryRobert M Rifkin, Sundar Jagannath, Brian G M Durie, et al.
Blood Advances|July 11, 2018
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MMSundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
British Journal of Haematology|August 6, 2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient RegistryHoward R Terebelo, Rafat Abonour, Cristina J Gasparetto, et al.
BMC Research Notes|October 24, 2024
Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician surveyChristopher R Henry, Scott D Walter, Peter Y Chang, et al.
Cancer Medicine|November 9, 2019
Connect MM Registry as a national reference for United States multiple myeloma patientsSikander Ailawadhi, Sundar Jagannath, Mohit Narang, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
British Journal of Haematology|October 29, 2020
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>®</sup> MM RegistryRafat Abonour, Robert M Rifkin, Cristina Gasparetto, et al.
Blood|September 25, 2001
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBLH J Deeg, B R Blazar, B J Bolwell, et al.
Blood Cancer Journal|November 11, 2024
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM RegistrySikander Ailawadhi, Hans C Lee, James Omel, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Annals of Hematology|July 30, 2018
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM RegistryRafat Abonour, Lynne Wagner, Brian G M Durie, et al.
Clinical Therapeutics|July 16, 2018
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM RegistryRobert M Rifkin, Sundar Jagannath, Brian G M Durie, et al.
Blood Advances|July 11, 2018
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MMSundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
British Journal of Haematology|August 6, 2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient RegistryHoward R Terebelo, Rafat Abonour, Cristina J Gasparetto, et al.
BMC Research Notes|October 24, 2024
Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician surveyChristopher R Henry, Scott D Walter, Peter Y Chang, et al.
Cancer Medicine|November 9, 2019
Connect MM Registry as a national reference for United States multiple myeloma patientsSikander Ailawadhi, Sundar Jagannath, Mohit Narang, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
British Journal of Haematology|October 29, 2020
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>®</sup> MM RegistryRafat Abonour, Robert M Rifkin, Cristina Gasparetto, et al.
Blood|September 25, 2001
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBLH J Deeg, B R Blazar, B J Bolwell, et al.
Blood Cancer Journal|November 11, 2024
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM RegistrySikander Ailawadhi, Hans C Lee, James Omel, et al.
Pageof 9